Monitor for FDA EOP2 meeting announcement and potential partnership/offering news. Given the low market cap and binary nature, position sizing should be minimal.
Price Chart
Executive Summary
Medicus Pharma announced positive dose-response results from an expanded analysis of its Phase 2 SKNJCT-003 study for Doxorubicin Microneedle Array (D-MNA) in nodular basal cell carcinoma. The 200µg cohort showed 55% histological clearance at Day 57 vs. 29% for device-only control, with a favorable safety profile. The data strengthens the registrational path ahead of End-of-Phase 2 discussions with the FDA, but the company has a $11M market cap and no approved products, making this an early-stage binary event.
Key Facts
- Expanded analysis of 69 patients with nodular BCC showed 200µg D-MNA achieved 55% histological clearance at Day 57 vs. 29% for device-only control.
- Clear dose-response relationship demonstrated, with 200µg cohort showing progressive improvement from Day 29 to Day 57.
- No drug-related serious adverse events or systemic doxorubicin toxicity reported; predominantly mild localized reactions.
- Company plans to advance toward End-of-Phase 2 (EOP2) discussions with FDA for registrational path.
Financial Impact
No financial data provided; company is pre-revenue with ~$2B market opportunity for BCC/Gorlin Syndrome.
Risk Factors
- FDA may not agree with registrational path or require additional studies.
- Company has no approved products and limited cash runway (not disclosed).
- Competition from existing BCC treatments (surgery, topical therapies).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3288692 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $2.51 $2.45 | ▼ −2.39% | ▼ −2.95% | $2.45 (−2.39%) |
Oct 16, 2026 10d ago | 8-K | $2.66 $2.72 | ▲ +2.45% | ▲ +2.11% | $2.45 (−7.72%) |
Oct 16, 2026 11d ago | SC 13G/A | $2.66 $2.72 | ▲ +2.45% | ▲ +2.11% | $2.45 (−7.72%) |
Oct 7, 2026 20d ago | 8-K | $0.1019 $0.0921 | ▼ −9.62% | ▼ −10.22% | $2.45 (+2304.32%) |
Sep 14, 2026 6w ago | 8-K | $0.1593 $0.1521 | ▼ −4.52% | ▼ −4.06% | $2.45 (+1437.98%) |
Sep 11, 2026 6w ago | 8-K | $0.1626 $0.1593 | ▲ +2.03% | ▲ +1.58% | $2.45 (−1406.77%) |
Sep 10, 2026 6w ago | Press Release | $0.1614 $0.1626 | ▲ +0.74% | ▼ −0.11% | $2.45 (+1417.97%) |
Sep 3, 2026 7w ago | 8-K | $0.1705 $0.1720 | ▲ +0.88% | ▲ +1.27% | $2.45 (+1336.95%) |
Jul 16, 2026 14w ago | Press Release | $0.4060 $0.3758 | ▼ −7.44% | ▼ −6.45% | $2.45 (+503.45%) |
May 14, 2026 23w ago | Press Release | $0.3010 $0.2910 | ▲ +3.32% | ▲ +3.26% | $2.45 (−713.95%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers